Z
Zai Lab
Built on a vision that China would be the next destination for the pharmaceutical and healthcare industry
About Zai Lab
Zai Lab is a biopharmaceutical company focused on developing and commercializing innovative therapies for oncology, infectious diseases, and autoimmune disorders. The company serves patients with unmet medical needs, primarily in China and the Asia-Pacific region. Operating in the highly competitive biopharmaceutical market, Zai Lab collaborates with global partners to license and develop cutting-edge treatments. The business model revolves around research and development (R&D), clinical trials, and commercialization of novel drugs. Revenue is generated through product sales, licensing agreements, and strategic partnerships. Zai Lab's facilities in Suzhou, China, are designed to meet international standards, ensuring high-quality manufacturing of small molecule and biologic drugs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2017
Open roles
Zai Lab in the Pudong ecosystem
The Zai Lab office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Qiming Venture Partners
Kleiner Perkins
Sequoia
TF Capital- ACAdvantech Capital
OrbiMed
Series B and later5 investors entered at this stage
Vivo Capital
Rock Springs Capital
Cormorant Asset Management- BCBank of Communications
Industrial Bank
Source: Dealroom Talent Intelligence.
Patents
9 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Zai Lab on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Zai Lab's zoci shows 40% response rate in hard-to-treat neuroendocrine cancers
Zai Lab raises $250M in PIPE to fund cancer drug development

